A5072174760- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Pharmaceutical studies and practices
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Breast Cancer Treatment Studies
- Ovarian cancer diagnosis and treatment
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Mechanisms and Therapy
- Cancer Research and Treatments
- Digestive system and related health
Bashkir State Medical University
2017-2025
Ministry of Health of the Russian Federation
2019-2025
Mother Hospital
2020-2025
Republican Oncological Clinical Dispensary
2014-2022
Ministry of Health
2021
Academy of Sciences of the Republic of Bashkortostan
2013
McGill University
2011
Georgetown University
2011
Georgetown University Medical Center
2011
Instituto Nacional de Cancerología
2011
BackgroundProlgolimab is an IgG1 anti–PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed efficacy and safety of two dosing regimens prolgolimab in patients with advanced melanoma a multicenter open-label parallel-arm phase II trial (MIRACULUM). present final analysis after 1 year follow-up additional results from 2 years follow-up.MethodsPatients cutaneous or non-cutaneous melanoma, including stable brain metastasis, without...
ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy quality of life.
Aim. To study the reasons for prescribing antitumor drugs (ATDs) beyond registered indications (BRIs) in real clinical practice. Materials and methods. The was conducted at Tula Regional Clinical Oncology Center. For 6 months of 2019, information analyzed on 919 completed cases treatment 201 patients over age 18 who received drug therapy morphologically verified solid malignant neoplasms inpatient department medical organization using a regional system. Completed with ATDs were copied BRIs...
Background . The major candidate genes for ovarian cancer (BRCA1/2) explain no more than 15–20 % of cases; therefore it is important to focus on the search new molecular genetic markers. aim study was analyze association rs11549465/HIF1A, rs3025039/VEGFA, and rs2146323/VEGFA polymorphic variants with risk developing in women from Republic Bashkortostan. Material methods Our research included DNA samples (n=205) without at time blood sampling (n=259) Genotyping carried out using Real Time PCR...
Background and objective — Gastric cancer (GC) is one of the most common cancers worldwide with a high mortality rate. Hereditary predisposition to GC still not fully understood. The this study was compare prevalence mutations in BRCA1 (c.68_69delAG, c.4035delA, c.5266dupC, c.3700_3704delGTAAA, c.3756_3759delGTCT, c.181T>G, c.1961delA), BRCA2 (c.5946delT), CHEK2 (c.1100delC, c.115+1G>A) NBS1 (c.657_661delGTTTT) genes patients healthy donors from Volga-Ural region Russia. Methods...
Neurologic symptoms caused by drug antitumor therapy remain a problem. The severity and frequency of development this type complications depend on the group, dose, duration use. Effective treatment requires proper approach to diagnosis toxic reactions. Therapy neurologic during should be based personalized due difference in mechanisms degree toxicity for each particular patient.Literature data main groups neurotoxic drugs, their action neurological administration are reviewed.
Genome instability – the increased tendency of acquiring mutations in genome and ability a cell to tolerate high mutation burden - is one drivers cancer. results from many causes including defects DNA repair systems. Previously, it has been shown that germline pathogenic Mismatch Repair (MMR) pathway cause cancer-predisposing Lynch Syndrome. We proposed Syndrome-related (LS-mutations) are associated with breast cancer (BC). In this study, we performed Targeted Next-Generation Sequencing MMR...
Lung cancer has the highest morbidity rate among all malignant tumors in men and mortality women Russia. In total, 49 145 new cases of lung were registered (diagnosed) Russia 2019. The majority are related to exogenic carcinogens mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations updated strategies including adjuvant anti-PD-L1 atezolizumab following completion chemotherapy...
88 Background: Advanced gastric cancer (GC) is an incurable disease. HER2 overexpression has been reportedin 6%–35% of and gastroesophageal tumors, whereas the EGFR upregulated in about 18%–28%. Clinical studies confirm that targeting combination with chemotherapy effective strategy, achieving a median survival ∼13.5 mos. Lapatinib, dual tyrosine kinase inhibitor EGFR, inhibits tumor growth modulates expression fluoropyrimidine-targeting genes. LPT109747 international, multicenter phase II...
An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to determine the association of lapatinib-induced fluoropyrimidine gene changes with efficacy lapatinib plus capecitabine as first-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma independent tumor HER2 status. Tumor biopsies obtained before and after 7-day (1,250 mg) analyze in expression, followed by a 14-day course (1,000 mg/m(2) twice daily, 14/21 days) 1,250 mg daily....
Gastric cancer (GC) is one of the most common types in world with a high mortality rate. Hereditary predisposition for GC not fully elucidated so far. The aim this study was identification possible new candidate genes, associated increased risk gastric development. Whole exome sequencing (WES) performed on 18 DNA samples from adenocarcinoma specimens and non-tumor-bearing healthy stomach tissue same patient. Three pathogenic variants were identified: c.1320+1G>A CDH1 gene...
удалить
Значительное количество злокачественных новообразований яичников являются наследственными (до 30% всех возникают в результате высокой генетической предрасположенности). Известно, по меньшей мере, 16 генов-кандидатов наследственного рака (РЯ), а с внедрением и широким применением полногеномного секвенирования растет число генов генетических вариантов, потенциально вовлеченных патогенез семейных форм заболевания, хотя вклад этих развитие РЯ еще предстоит доказать. Обнаружение специфических...
.
20 Background: The results of the 5-year overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) has been reported rarely. aim RENSUR5 registry study was to obtain real-world data on use therapies mRCC and assess OS Russian population. Methods: Patients were retrospectively identified at 11 cancer centers different regions Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St.Petersburg, Ufa). included if diagnosed from...
Background: Defects in DNA damage recognition and repair has been implicated hereditary breast cancer (BC). Several studies demonstrated, that Fanconi Anemia (FA) associated genes-coding proteins products of BRCA1/2 genes cooperate a pathway which is required for resistance to interstrand crosslinks. Our aim was analyze nucleotide variants FA predisposing with an increased risk cancers. Methods: Targeted NGS performed cohort 630 BC patients strong evidence background cancer. The...
Epidermal Grows factor receptor (EGFR) is one of the most significant and studied signaling pathway, regulating growth, survival, proliferation differentiation mamllian cells. At same time EGFR its protein family play a central role in pathogenesis progression different type tumors. In 80-s, it was proposed that this pathway could be target for therapy. Today there are 3 generations tyrosine kinase inhibitors (TKIs). This drug class actively used clinical practice therapy patients with...